Erika Hamilton, Medical Oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute, posted on LinkedIn:
“In advance of seeing some PROTAC data at ASCO25 in the MBC oral session, happy to share our review manuscript recently published for some background of how these anti-estrogen compounds work and why they are different from existing endocrine therapies.”
Title: PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Authors: Erika P. Hamilton, Rinath M. Jeselsohn, Linda T. Vahdat, Sara A. Hurvitz
Read The Full Article at Springer Nature Link.
More posts featuring Erika Hamilton on OncoDaily.